Mereo BioPharma Group (MREO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Mereo BioPharma Group (MREO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.06

-0.28 (-8.38%)

At close: Jan 14, 2025, 3:59 PM

3.07

0.33%

Pre-market Jan 15, 2025, 05:13 AM EST

undefined% (undefined)

Bid	3.05
Market Cap	473.49M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.3
PE Ratio (ttm)	-10.2
Forward PE	n/a
Analyst	Buy

Ask	3.86
Volume	1,698,857
Avg. Volume (20D)	881,359
Open	3.39
Previous Close	3.34
Day's Range	2.91 - 3.39
52-Week Range	2.52 - 5.02
Beta	undefined

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 24, 2019

Employees 33

Stock Exchange NASDAQ

Ticker Symbol MREO

Website https://www.mereobiopharma.com

Analyst Forecast

According to 6 analyst ratings, the average rating for MREO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 128.76% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+8.65%

Mereo BioPharma shares are trading higher after Je... Unlock content with Pro Subscription

7 months ago · Source

+8.81%

Mereo BioPharma shares are trading higher after the company and Ultragenyx Pharmaceutical announced 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.

News

1 month ago · seekingalpha.com

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from ...